Options for Down syndrome screening: What will women choose?

被引:15
作者
Grant, SS [1 ]
机构
[1] Univ Iowa Hlth Care, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
关键词
Down syndrome; first trimester; integrated screening nuchal translucency; FASTER trial;
D O I
10.1016/j.jmwh.2005.01.008
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Down syndrome screening has been offered to pregnant women since the early 1980s. Protocols have changed as research confirmed improvements that result in higher detection rates and lower false-positive rates. Results from 2 clinical trials evaluating screening protocols that include ultrasound measurement of nuchal translucency and biochemical testing in the first and second trimester are now available. First-trimester screening is an option if there are adequate ultrasound, diagnostic, and counseling services available. Regional variation in the availability of these services may limit the implementation of first-trimester screening. Combining screening tests for Down syndrome from both trimesters as an integrated test offers the highest detection rate with the lowest false-positive rate. The possibility of avoiding a positive screen will make this an attractive option for some. Timing, detection rate, false-positive rates, and personal factors influence the decision women make regarding screening versus diagnostic testing. This article reviews the efficacy of current protocols for Down syndrome screening. Accurate information about available screening tests will facilitate informed decisions about screening and testing. (c) 2005 by the American College of Nurse-Midwives.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 40 条
  • [11] *COMM ED B AM COLL, 1996, ED B, V228
  • [12] Filly RA, 2000, J ULTRAS MED, V19, P1
  • [13] Communicating risk in prenatal genetic testing
    Gates, EA
    [J]. JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2004, 49 (03) : 220 - 227
  • [14] Green Josephine, 1996, TROUBLED HELIX SOCIA, P140
  • [15] In response to 'Certificate of competence in performing specific procedures or tests in screening practice'
    Greene, N
    Platt, LD
    [J]. PRENATAL DIAGNOSIS, 2004, 24 (04) : 315 - 315
  • [16] CHROMOSOMAL ABNORMALITY RATES AT AMNIOCENTESIS AND IN LIVE-BORN INFANTS
    HOOK, EB
    CROSS, PK
    SCHREINEMACHERS, DM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 249 (15): : 2034 - 2038
  • [17] First- and second-trimester evaluation of risk (faster) trial: Principal results of the NICHD multicenter down syndrome screening study
    Malone, FD
    Wald, NI
    Canick, JA
    Ball, RH
    Nyberg, DA
    Comstock, CH
    Bukowski, R
    Berkowitz, RL
    Gross, SJ
    Dugoff, L
    Craigo, SD
    Timor, IE
    Carr, SR
    Wolfe, HM
    Dukes, KA
    Bianchi, DW
    Rudnicka, A
    Hackshaw, A
    Lambert-Messerlian, G
    D'Alton, ME
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (06) : S56 - S56
  • [18] First-trimester sonographic screening for Down syndrome
    Malone, FD
    D'Alton, ME
    [J]. OBSTETRICS AND GYNECOLOGY, 2003, 102 (05) : 1066 - 1079
  • [19] First-trimester screening for aneuploidy: Research or standard of care?
    Malone, FD
    Berkowitz, RL
    Canick, JA
    D'Alton, ME
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (03) : 490 - 496
  • [20] Decisions about amniocentesis by advanced maternal age patients following maternal serum screening may not always correlate clinically with screening results: Need for improvement in informed consent process
    Marini, T
    Sullivan, J
    Naeem, R
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 109 (03): : 171 - 175